Entrada Therapeutics, Inc. (NASDAQ:TRDA) COO Nathan J. Dowden Sells 847 Shares

Entrada Therapeutics, Inc. (NASDAQ:TRDA) COO Nathan J. Dowden sold 847 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $16.00, for a total value of $13,552.00. Following the transaction, the chief operating officer now directly owns 125,149 shares in the company, valued at $2,002,384. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Entrada Therapeutics Stock Up 0.1 %

Shares of TRDA opened at $16.00 on Wednesday. The business’s 50 day moving average is $15.70 and its two-hundred day moving average is $14.89. Entrada Therapeutics, Inc. has a 52-week low of $10.75 and a 52-week high of $18.17. The firm has a market cap of $595.20 million, a price-to-earnings ratio of 24.14 and a beta of -0.24.

Entrada Therapeutics (NASDAQ:TRDA) last announced its earnings results on Tuesday, August 13th. The company reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.90. Entrada Therapeutics had a return on equity of 35.16% and a net margin of 43.63%. The company had revenue of $94.69 million for the quarter, compared to analyst estimates of $55.00 million. On average, equities analysts expect that Entrada Therapeutics, Inc. will post 0.68 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Entrada Therapeutics

Institutional investors have recently made changes to their positions in the business. Allspring Global Investments Holdings LLC increased its holdings in shares of Entrada Therapeutics by 427.6% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock valued at $209,000 after acquiring an additional 11,965 shares during the last quarter. New York State Teachers Retirement System bought a new stake in shares of Entrada Therapeutics in the 1st quarter valued at approximately $27,000. Vanguard Group Inc. increased its holdings in shares of Entrada Therapeutics by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company’s stock valued at $15,288,000 after acquiring an additional 13,742 shares during the last quarter. Acadian Asset Management LLC bought a new stake in shares of Entrada Therapeutics in the 1st quarter valued at approximately $79,000. Finally, Bank of New York Mellon Corp increased its holdings in shares of Entrada Therapeutics by 13.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 125,436 shares of the company’s stock valued at $1,787,000 after acquiring an additional 14,838 shares during the last quarter. 86.39% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently commented on the company. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Entrada Therapeutics in a research report on Wednesday, August 14th. Oppenheimer reissued an “outperform” rating and set a $25.00 price target on shares of Entrada Therapeutics in a research report on Monday, August 26th.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.